Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 2/23/2021 (updated 4/4/2024)
RCORP Planning 3 Reference Guide
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.
Posted 9/15/2021 (updated 4/3/2024)
The MOUD Best Practices Webinar series takes a person-centered, outcomes-focused approach to presenting and discussing best practices in the use of medication for opioid use disorder (MOUD), starting with client engagement and initiation of MOUD, patient stabilization and retention in MOUD, and supporting recovery during MOUD. The focus of each presentation in the series will be on the application of best practices to meet your community’s goals for each of the three topic areas, including adapting them to your local resources while maintaining fidelity to their evidence base.
At the conclusion of Session 1, participants will be able to: describe specific best practices related to engagement and initiation of MOUD, connect best practices to the community’s outcomes and goals and adapt best practices to local needs and resources while maintaining fidelity to the evidence base.
Presenter: Melinda Campopiano, MD (mcampopiano@jbsinternational.com)
Posted 2/29/2024 (updated 3/28/2024)
The 2024 RCORP-Behavioral Health Care Support Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA.
Posted 7/22/2020 (updated 3/28/2024)
The Data Sharing among Criminal Justice & Behavioral Health Partners: Addressing Data Sharing Agreements & Confidentiality Concerns Webinar was held June 24, 2020. The resources from this webinar are shared below.
Posted 4/12/2022 (updated 3/27/2024)
Since 1999, an estimated 841,000 people in the U.S. have died from a drug overdose. Beginning in March 2020, the COVID-19 pandemic significantly exacerbated the overdose crisis resulting in a 30% increase in 2020 compared to 2019. The majority of overdose deaths in the U.S. involve opioids, including nearly 71% of all overdose deaths in 2019.3 Despite high rates of overdose across the nation, overdose and overdose death are preventable. However, people at risk of overdose often face significant challenges accessing treatment and navigating systems of care. Local and state health departments are well-suited to lead and support efforts to prevent and respond to overdose and to link people to evidence-based treatment and services. Peer support services (PSS) are a valuable component of a growing number of overdose response and linkage to care initiatives that can be implemented and supported by local and state health departments.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs